Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Lumos Pharma
Lumos Pharma
Hoffmann-La Roche
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Eli Lilly and Company
Ohio State University Comprehensive Cancer Center
Eli Lilly and Company
Pfizer